Company Description
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company.
It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM).
In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions.
It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.
Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Robert Goodman |
Contact Details
Address: 900 Stewart Avenue, Suite 301 Garden City, New York 11530 United States | |
| Phone | 516 665 8200 |
| Website | beyondair.net |
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1641631 |
| CUSIP Number | 08862L301 |
| ISIN Number | US08862L3015 |
| Employer ID | 47-3812456 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert Scott Goodman | Chief Executive Officer and Director |
| Amir Avniel | Chief Executive Officer of NeuroNOS |
| Michael A. Gaul | Chief Operating Officer |
| Denton Drewell | Principal Accounting Officer and Controller |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board |
| Dr. John Jett Ph.D. | Head of Research and Clinical Development |
| Adam T. Newman | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2026 | SCHEDULE 13G/A | Filing |
| Jul 14, 2026 | SCHEDULE 13G | Filing |
| Jul 9, 2026 | 8-K | Current Report |
| Jun 26, 2026 | 8-K | Current Report |
| Jun 26, 2026 | 10-K | Annual Report |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 5, 2026 | DEF 14A | Other definitive proxy statements |